An open label,randomized control study for the comparison of pliotropic effects between Glulisine and Glargine with type 2 diabetes

Not Applicable

• Conditions: type 2 diabetes

• Registration Number: JPRN-UMIN000010353
• Lead Sponsor: Department of Disease Control and Homeostasis,kanazawa University Graduate School of Medical Science.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-03-28
• Study Completion: 2014-06-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1.Hypersensitivity to components of the insulin glargine and insulin glulisine. 2.None Type 2 diabetes 3.Medical history and/or complication of diabetic ketoacidosis. 4.Medical history and/or complication of severe hypoglycemia. 5.severe infection, around surgery or severe trauma. 6.Patients who received the administration of insulin, DPP-4 inhibitors or GLP-1 analog formulation within 4 weeks. 7.Treatment with glucocorticoid. 8.Uncontrolled Hypertension(systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg) 9.Proliferative retinopathy or maculopathy. 10.History of malignancy. 11.Severe health problems not suitable for the study. 12.Patients participated in other clinical trials within one month before the study. 13.Cases that Physicians deem inappropriate as the target of the test.

Study & Design

• Study Type: Interventional
• Study Design: Not specified